1 January 2011PatentsArchana Shanker

A revolution: biotech patents in India

In May 2011, Glenmark Pharmaceuticals entered into a licence agreement with Sanofi Aventis in one of the first-ever deals for a novel biologic molecule in India for the treatment of autoimmune diseases. Bharat Biotech, an Indian Biotech company, developed a diarrhoea vaccine to be supplied to the UN and other markets at $1 each, making it the cheapest vaccine available in the market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

India: Patents-in-waiting

23 September 2019 With pendency rates ranging up to four years, India’s patent owners have a range of options to protect their innovations while they wait, explains Joginder Singh of LexOrbis.

Jurisdiction reports

India jurisdiction report: Defending domain names

14 August 2020 With the rapid growth of the internet and globalisation, the marketing of products and services through websites and domain names has become a vital part of brand-building and commerce for trademark owners.

Huawei wins seven-country ban on Netgear routers at the UPC

Lenovo faces US import ban as ITC sides with Ericsson

Arusha Protocol takes root: Fresh growth for plant variety protection in Africa

‘The politics of AI are developing’: Will Trump give tech a free ride?

China: Unpacking the first successful patent invalidation due to unauthorised foreign filing

SharkNinja overturns Dyson’s vacuum ban at the UPC

On our radar… Smashburger, OpenAI, Feminist Cyberlaw

IP strategy for AI should be a ‘living, breathing organism’

A revolution: biotech patents in India

More on this story

Editor's picks

Editor's picks

More articles